Literature DB >> 25236668

Healing of granulomatous skin changes in ataxia-telangiectasia after treatment with intravenous immunoglobulin and topical mometasone 0.1% ointment.

Emily D Privette1, Gita Ram, James R Treat, Albert C Yan, Jennifer R Heimall.   

Abstract

Ataxia-telangiectasia (AT) is a rare autosomal recessive disorder characterized by faulty DNA damage repair. The disease affects multiple systems and is noted to be particularly difficult to diagnose in children because of the wide spectrum of clinical presentations. We present an unusual case of a child in whom the primary cutaneous manifestation of AT was noninfectious cutaneous caseating granulomas. A 3-year-old girl presented to the emergency department with ataxia, poor growth, and multiple ulcerated plaques on both upper extremities that had been present for 2 years. She had two prolonged hospitalizations and underwent extensive examination to identify an etiology for the skin lesions. She was diagnosed with AT after immunology examinaton and genetic testing. Outpatient intravenous immunoglobulin (IVIG) therapy was initiated and she was prescribed twice-daily mometasone 0.01% ointment under occlusion. After 6 weeks on this regimen her lesions had completely healed. Twenty-two cases of AT have been reported in which patients presented with cutaneous granulomas. This report demonstrates the first reported case in which the granulomatous skin lesions of AT healed after aggressive application of topical steroids with concurrent IVIG therapy, without oral steroids. A brief review of cutaneous granulomas in the setting of immunodeficiency is also presented.
© 2014 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25236668     DOI: 10.1111/pde.12411

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  6 in total

1.  Outcomes for Nitazoxanide Treatment in a Case Series of Patients with Primary Immunodeficiencies and Rubella Virus-Associated Granuloma.

Authors:  Ludmila Perelygina; David Buchbinder; Morna J Dorsey; Marc Eloit; Fabian Hauck; Timo Hautala; Despina Moshous; Ignacio Uriarte; Elena Deripapa; Joseph Icenogle; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2019-01-24       Impact factor: 8.317

2.  Neutrophil oxidative burst activates ATM to regulate cytokine production and apoptosis.

Authors:  C J Harbort; Paulo Vitor Soeiro-Pereira; Horst von Bernuth; Angela M Kaindl; Beatriz Tavares Costa-Carvalho; Antonio Condino-Neto; Janine Reichenbach; Joachim Roesler; Arturo Zychlinsky; Borko Amulic
Journal:  Blood       Date:  2015-10-21       Impact factor: 22.113

Review 3.  Ataxia telangiectasia: a review.

Authors:  Cynthia Rothblum-Oviatt; Jennifer Wright; Maureen A Lefton-Greif; Sharon A McGrath-Morrow; Thomas O Crawford; Howard M Lederman
Journal:  Orphanet J Rare Dis       Date:  2016-11-25       Impact factor: 4.123

4.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

5.  Treatment of Granulomas in Patients With Ataxia Telangiectasia.

Authors:  Sandra Woelke; Eva Valesky; Shahrzad Bakhtiar; Helena Pommerening; L M Pfeffermann; Ralf Schubert; Stefan Zielen
Journal:  Front Immunol       Date:  2018-09-18       Impact factor: 7.561

Review 6.  Inflammation, a significant player of Ataxia-Telangiectasia pathogenesis?

Authors:  Majid Zaki-Dizaji; Seyed Mohammad Akrami; Gholamreza Azizi; Hassan Abolhassani; Asghar Aghamohammadi
Journal:  Inflamm Res       Date:  2018-03-26       Impact factor: 4.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.